The Pharma Letter1h
FDA places clinical hold on BioNTech malaria trial
German biotech major BioNTech (Nasdaq: BNTX) has suffered a blow as it seeks to add new revenue streams beyond its COVID-19 ...
Berenberg Bank Sticks to Its Buy Rating for BioNTech SE (BNTX)
In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...
FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine
BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...
FDA puts clinical hold on BioNTech’s malaria vaccine trial
The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.
Endpoints News22h
FDA puts BioN­Tech’s malar­ia vac­cine on clin­i­cal hold
BioNTech has paused an early-stage study of its experimental malaria vaccine after the FDA handed it a clinical hold, the ...
BioSpace23h
FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount
The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC ...